Central serous chorioretinopathy and glucocorticoids.
Central serous chorioretinopathy is a relatively common retinal disease characterized by the accumulation of subretinal fluid at the posterior pole of the fundus, creating a circumscribed area of serous retinal detachment. It typically affects young and middle-aged men with no previous medical and family history, and no systemic symptoms or signs. However, it has been noted that central serous chorioretinopathy is associated with different conditions, characterized by exposure to increased levels of endogenous or exogenous glucocorticoids. In fact, central serous chorioretinopathy has been described in patients with endogenous Cushing's syndrome. It is also prevalent in patients with type-A behavior, and following stressful events, and pregnancy probably represents a risk factor for central serous chorioretinopathy; these conditions are characterized by endogenous hypercortisolism. In addition, many cases of central serous chorioretinopathy have been described during or following treatment with glucocorticoids, administrated by any route, for various systemic or ocular conditions. Central serous chorioretinopathy, when related to the exposure to exogenous glucocorticoids, has a less prominent male predilection, presents more often with a chronic or atypical form, and is frequently bilateral. Furthermore, treatment of central serous chorioretinopathy with glucocorticoids was found to exacerbate the clinical picture. Based on these observations it could be suggested that glucocorticoids may be involved in the development of central serous chorioretinopathy, even though the exact pathogenic mechanism remains unclear. Glucocorticoids should not be used in the treatment of central serous chorioretinopathy and central serous chorioretinopathy should be added to the list of ocular complications of glucocorticoids.
Bouzas
Evrydiki A
EA
Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece.
Karadimas
Panagiotis
P
Pournaras
Constantin J
CJ
D000308:Adrenocortical Hyperfunction / Q000150:complications; D015862:Choroid Diseases / Q000139:chemically induced* / Q000209:etiology; D000075202:Contraindications; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D012164:Retinal Diseases / Q000139:chemically induced* / Q000209:etiology
D005938:Glucocorticoids